| __timestamp | Alnylam Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 2704597 |
| Thursday, January 1, 2015 | 276495000 | 15470000 |
| Friday, January 1, 2016 | 382392000 | 28037000 |
| Sunday, January 1, 2017 | 390635000 | 71615000 |
| Monday, January 1, 2018 | 505420000 | 99828000 |
| Tuesday, January 1, 2019 | 655114000 | 166023000 |
| Wednesday, January 1, 2020 | 654819000 | 201727000 |
| Friday, January 1, 2021 | 792156000 | 259039000 |
| Saturday, January 1, 2022 | 883015000 | 294781000 |
| Sunday, January 1, 2023 | 1004415000 | 344077000 |
| Monday, January 1, 2024 | 1126232000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. exemplify this focus, with Alnylam consistently outspending Iovance in R&D over the past decade. Since 2014, Alnylam's R&D expenses have surged by over 400%, reaching a peak in 2023. In contrast, Iovance's R&D spending, while also growing, has increased by approximately 127% during the same period. This disparity highlights Alnylam's aggressive pursuit of innovation, potentially positioning it as a leader in the biotech sector. The data underscores the importance of R&D in driving advancements and maintaining a competitive edge in the rapidly evolving field of biotechnology.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Grifols, S.A. or Iovance Biotherapeutics, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development Investment: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Iovance Biotherapeutics, Inc. vs MiMedx Group, Inc.